Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2868 injection in advanced hepatocellular carcinoma after anti-angiogenic and immune checkpoint inhibitor failure
CTR20230536Phase 2Terminated
- Sponsor
- Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2868 in hepatocellular carcinoma (HCC), sponsored by Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Started Feb 2023; status: terminated.
02
Drugs
TQB2868
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20230536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230536.